ArticleEuropean journal of breast health2026
Cost of Breast Cancer Treatment by Comorbidity in Dubai, the United Arab Emirates: A Retrospective Data Analytical Approach.
Article in European journal of breast health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Breast cancer is the most common malignancy among women in Dubai, yet the economic burden of its treatment remains understudied. This study aimed to estimate the direct medical costs of breast cancer care in Dubai in 2024 and to examine variations by encounter type, comorbidity burden, and provider setting. Materials and Methods: A retrospective cross-sectional analysis of insurance claims was conducted for January-December 2024. Breast cancer cases were identified using International Classification of Diseases, 10 Results: A total of 8,967 patients (mean age 51.8 years) with 81,248 claims were identified. Outpatient visits constituted 86% of encounters and accounted for 81% of total expenditure (USD 48.7M). Inpatient admissions accounted for 6% of encounters and had the highest mean cost per patient (USD 10,808). The total expenditure was USD 60.0M. Costs increased significantly with comorbidity severity: patients with CCI ≥5 incurred 6.4-fold higher costs compared to those without comorbidities (p<0.0001). Hospital-based care increased costs by 16%, and pharmacy claims contributed an additional 31% to expenditures. Conclusion: Breast cancer treatment in Dubai imposes a substantial economic burden, largely driven by outpatient services, hospital-based care, and medication costs. Comorbidity significantly increases expenditures. These findings highlight the importance of integrated, risk-stratified care pathways and sustainable strategies to optimize resource allocation for breast cancer management in the United Arab Emirates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.